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Abstract
Background: Genome-wide studies on autism spectrum disorders (ASDs) have mostly focused on large-scale
population samples, but examination of rare variations in isolated populations may provide additional insights into
the disease pathogenesis.
Methods: As a first step in the genetic analysis of ASD in Croatia, we characterized genetic variation in a sample of
103 subjects with ASD and 203 control individuals, who were genotyped using the Illumina HumanHap550
BeadChip. We analyzed the genetic diversity of the Croatian population and its relationship to other populations,
the degree of relatedness via Runs of Homozygosity (ROHs), and the distribution of large (>500 Kb) copy number
variations.
Results: Combining the Croatian cohort with several previously published populations in the FastME analysis (an
alternative to Neighbor Joining) revealed that Croatian subjects cluster, as expected, with Southern Europeans; in
addition, individuals from the same geographic region within Europe cluster together. Whereas Croatian subjects
could be separated from a sample of healthy control subjects of European origin from North America, Croatian
ASD cases and controls are well mixed. A comparison of runs of homozygosity indicated that the number and the
median length of regions of homozygosity are higher for ASD subjects than for controls (p = 6 × 10
–3).
Furthermore, analysis of copy number variants found a higher frequency of large chromosomal rearrangements
(>2 Mb) in ASD cases (5/103) than in ethnically matched control subjects (1/197, p = 0.019).
Conclusions: Our findings illustrate the remarkable utility of high-density genotype data for subjects from a limited
geographic area in dissecting genetic heterogeneity with respect to population and disease related variation.
Background
Autism Spectrum Disorders (ASD, MIM209850) are a
severe neuropsychiatric disorders, primarily character-
ized by abnormalities in social behavior, communication
and language, with patterns of restricted and repetitive
interests [1]. Commonly associated symptoms include
aggressive and self-injurious behaviors, anxiety, heigh-
tened sensitivity to stimuli, and seizures [2,3]. Severity
of symptoms in ASD can vary widely among cases, from
individuals with mental retardation and no language
production to relatively high-functioning individuals
with normal to superior intelligence but significant diffi-
culties with social interaction [4-6].
Multiple lines of evidence converge to suggest that
ASDs represent the most heritable neurodevelopmental
and psychiatric conditions. Evidence from twin and
family studies suggests that the rate of autism in siblings
of affected individuals is 2-6% [7], with 92% concor-
dance of ASD in monozygotic twins and over 10% con-
cordance in dizygotic twins [8]. Previous linkage and
candidate gene studies have identified several chromoso-
mal regions with autism susceptibility loci [3,9-13].
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underlying ASD employing a genome-wide association
strategy in 780 families (3,101 subjects) with affected
children, and a second cohort of 1,204 affected subjects
and 6,491 control subjects; these findings were repli-
c a t e di na ni n d e p e n d e n ts t u d yc o h o r to f4 8 3A S D
families [14]. Furthermore, substantial progress towards
the identification of genetic risk variants has come from
recent characterization of structural variation (i.e.,c o p y
number variation or CNV). Studies of CNVs in a cohort
of 859 ASD cases and 1,400 healthy control children
revealed structural variants in previously reported ASD
candidate genes (NRXN1 and CNTNAP4) and in multi-
ple novel susceptibility genes encoding cell-adhesion
molecules, including NLGN1 and ASTN2.F u r t h e r m o r e ,
CNVs observed in cases but not controls were found
within and surroundings genes involved in the ubiquitin
pathway (UBE3A, PARK2, RFWD2 and FBXO40)[ 1 5 ] .
In a related study, we performed high-density genotyp-
ing and obtained data on 3,832 individuals from 912
multiplex ASD families in the Autism Genetic Research
Exchange (AGRE) and 1,489 unrelated control subjects.
Through prioritization of exonic deletions (eDels), we
recovered genes in which structural variants were pre-
sent in multiple unrelated probands but not unrelated
controls. The 42 genes identified by this method include
NRXN1, UBE3A, MADCAM1 and BZRAP1 [16]. Studies
of large families with shared ancestry have reported sev-
eral other autism loci including large, inherited, homo-
zygous deletions in neuronal cell-adhesion genes, for
example PCDH10 (protocadherin 10) [17]. These find-
ings highlight the utility of “homozygosity mapping” and
a need to search for additional large families across
diverse populations.
Based on these breakthroughs and lessons learned
from studies of other complex diseases (i.e. diabetes and
breast cancer), it is becoming apparent that there is a
need to assess large sample collections that number in
the tens of thousands. Population structure poses a chal-
lenge for large-scale disease-association studies; mis-
matched ancestry between cases and controls in a
genome-wide association studies is a potential source of
spurious associations [17]. These needs and challenges
bring together usually separated fields of genetics, epide-
miology and studies of human diversity. Also, it is
important to relate genetic findings found in patients
from developed countries to the studies of diverse popu-
lations in less developed parts of the world. Currently
DNA has been assembled from only a few thousand
individuals with autism worldwide. Significant advances
in genetic analyses of ASD in diverse populations will
require the collection of samples across many popula-
tions using rapid and affordable screening and diagnos-
tic tools.
Isolated populations have contributed to the discovery
of genetic factors for many Mendelian disorders [18]. It
has been argued that isolated populations may facilitate
the identification of susceptibility loci for complex dis-
eases because of a reduced genetic diversity, i.e. reduced
genetic heterogeneity [19,20]. Although several Croatian
island populations have been described as genetic iso-
lates, the Croatian population as a whole does not
represent a population isolate as conventionally defined
[21,22]. However, Croatia is a small country with a low
migration rate, in which large extended families often
live in the same household or same neighbourhood and,
therefore, is perfectly suited for family-based genetic
studies. We expect that a subset of affected individuals
m a ys e g r e g a t eal i m i t e dn u m b e ro fc a u s a t i v eA S Ds u s -
ceptibility alleles (causal variants); in some cases these
loci or disease-associated haplotypes identified in genetic
isolates may differ from those in more genetically
diverse populations, such as Europeans in North Amer-
ica. We also expect that a subset of rare variants asso-
ciated with ASD susceptibility (SNPs and CNVs), which
were identified in a large set of Europeans from North
America, may be more prevalent in specific ethnic
groups like the Croats. Therefore, to improve our
understanding of global patterns of human genetic var-
iation and set the stage for large-scale disease studies,
efforts are underway to evaluate genetic variation using
high-density genotype data for human populations
worldwide [23-25].
With the intention to use the Croatian population in
future genome-wide association studies, we performed a
g e n o m e - w i d eh i g h - d e n s i t yg e n o t y p ep i l o ts t u d yo f1 0 3
ASD cases and 203 control samples to characterize the
genetic structure of the population. Our analysis focuses
on (1) the genetic diversity of the Croatian population,
and its relationship to other populations, (2) the degree
of relatedness of the population through the analysis of
Runs of Homozygosity (ROHs), and (3) the distribution
of large (>500 Kb) copy number variations, a major
mechanism for structural variation in human genomes,
and its possible association with ASD.
Results and Discussion
To understand the complexities of genomic architecture
of ASDs, a highly heterogeneous group of disorders, and
to assess the distribution and specificity of common and
rare variants in different populations, we initiated geno-
mic analysis of ASD and control subjects from Croatia.
This cohort, consisting of 103 subjects (children and
adults) with ASD and 203 adult control subjects, with
male-to-female ratios of 3.7:1 (in ASD) and 2.6:1 (in
controls), was originally recruited to study the role of
hyperserotonemia in autism [26-28]. Patients with aut-
ism were evaluated by a child psychiatrist and diagnoses
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Page 2 of 19were based on DSM-IV-TR [29] criteria. Severity of
behavioral symptoms was measured using the Childhood
Autism Rating Scale (CARS) [30]. The degree of mental
retardation (MR) was assessed according to the standar-
dized intelligence or developmental tests, corresponding
to the apparent developmental level of each individual.
ASD in selected families occurs either in the absence of
positive family history (sporadic) or in families with a
high prevalence of other clinical psychiatric disorders
distinct from ASD (such as anxiety, depression and pho-
bias). During the clinical assessment and interviews, psy-
chiatrists and geneticists did not notice any recognizable
dysmorphic features in selected study subjects. DNA
samples isolated from whole blood were genotyped with
the Illumina HumanHap550 SNP array and 306 samples
gave high quality data that were subjected to population
structure and CNV analysis. See Table 1 for a summary
of the genome-wide datasets used in this study.
To understand the genetic homogeneity of the Croa-
tian cohort and its position in the worldwide human
population, we used phylogenetic tree analysis, principal
component analysis (PCA) (not shown), and multi-
dimensional scaling (MDS), three tools commonly used
in the study of human population genetic diversity
[23,24]. We used data from the Human Genome Diver-
sity Project (HGDP), which consists of genome-wide
SNP data of 1007 individuals from 51 populations,
divided into 7 geographic regions. Of these individuals,
153 were from 8 populations from the European region.
We plotted the results of MDS and tree analyses using
control subjects from Croatia and the HGDP samples
(Figure 1). All three methods show the same overall pat-
tern emerging from previous HGDP studies: the relative
positions of the major regions largely correlate with
their relative geographical locations, and reflect the
human migration history well. Humans migrated from
Africa to the Middle East (Figure 1A-B); the first
branching took place, and one group migrated to Eur-
ope, while the other migrated to South Asia. A second
major branching then occurred, with one migration to
America (through Alaska), the other countinuing to East
Asia and eventually Oceania. As expected, the Croatia
control samples are entirely contained within the Eur-
opean samples. A focused analysis of Europeans in the
HGDP panel (Figure 1C-D) with the Croatia control
samples situated in the middle of phylogeny or MDS
plots shows the relationship of this subpopulation to
other European populations. The Sardinians and the
Basques seem to be the farthest, with Italian samples
placed in between them and the Croatian controls; the
other subpopulation that is separate from the Croatia
controls is the Adygei. The Croatians are most similar
to the Russians and the Orcadians. Both the PCA (not
shown) and MDS plots show the relative diversity of the
Croatian controls (indicated by the area spanned by the
samples on the MDS and PCA plots) to be similar to
the other populations. The boxplot of pairwise Identity
by State (IBS) distances for European populations (Fig-
ure 2A) showed the Croatian control cohort has diver-
gence similar to other European subpopulations (except
Basques and Sardinians who are genetically more homo-
geneous), and smaller than the European population as
a whole.
We performed MDS on the Croatian controls and
cases, as well as NINDS (National Institute of Neurolo-
gical Disorders and Stroke) control cohorts to check the
relationships between the three cohorts (Figure 2B), and
found that the Croatian control and cases are well
mixed but separate from the NINDS controls. Randomi-
zation tests by shuffling between Croatian control and
NINDS controls showed the median pairwise IBS (iden-
tity-by-state) distance across the two subsets (0.28) is
significantly higher than expected by chance (p =
0.00273, see Figure 3); this agrees with the MDS visuali-
zation that the two cohorts are genetically separate.
Analysis of fixation index (FST) led to the same conclu-
sion (see Table 2 for top regions with large FST). In
summary, the Croatian and the NINDS cohorts have
significant genetic difference, and care must be taken to
correct for population stratification in combining the
two datasets for association studies.
Mapping of large regions of homozygosity in pedigrees
with shared ancestry has been employed in the discovery
of autosomal recessive diseases associated with neurode-
velopmental anomalies [31-33], and more recently, in
the identification of novel genes associated with ASD,
schizophrenia and Alzheimer’s Disorder [17,34,35].
Although we recruited unrelated ASD cases and healthy
controls, we analyzed genome-wide rates of homozygos-
ity to estimate consanguinity and compared these rates
to a heterogeneous control sample of Europeans from
Table 1 Summary of datasets with whole-genome
genotyping
Dataset #Subjects #Case Platform #SNPs
Croatia (Before QC) 306 103 Illumina
550 K
561,466
(After QC) 305 103 489,200
NINDS (Before QC) 542 0 Illumina
550 K
561,466
(After QC) 534 0 489,096
HGDP (Before QC) 1,043 0 Illumina
650Y
660,918
(After QC) 1,043 0 584,835
Merged datasets
Croatia+NINDS (After QC) 839 103 - 475,964
Croatia+HGDP (After QC) 1,348 103 - 478,287
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extended tracks of homozygosity may facilitate identifi-
cation of low-frequency variants associated with com-
plex diseases [36,37]. We detected regions (“runs”)o f
homozygosity (ROH) using the PLINK v1.05 software
[38] and compared the extent of homozygosity in Croa-
tia ASD cases, control subjects and NINDS controls.
We computed the number of ROH segments, total
ROH length, and average ROH length for the three sub-
sets (Table 3). We detected subtle differences between
the three groups for the median number of ROHs
(Kruskal-Wallis test; p = 0.06), as well as average ROH
length between Croatia controls and NINDS controls
(Wilcoxon test; p = 0.053), with NINDS cohort showing
shorter total ROH length than Croatia controls (Krus-
kal-Wallis test; p = 0.0056, higher due to the very large
number of NINDS samples). However, the most signifi-
cant pairwise difference is the total ROH length between
Croatian cases Croatian controls (Wilcoxon test; p =
0.0065).
Motivated by the study demonstrating the positive
correlation between runs of homozygosity and age in a
North American cohort of European descent due to
urbanization [35], we examined age correlation with
ROH frequency and size in the 103 ASD subjects (Fig-
ure 4 and Table 4). We found only borderline signifi-
cance between age and average ROH size, though the
lack of significance may be due to the fact that the
Croatia ASD cohort is 40 years younger (mean age is
21.5 y as opposed to 61.7 y in Nalls et al. [35]).
ROH regions were common or specific for a demo-
graphic group (Croatia vs. North America) or a disease
status (ASD vs. controls). Although the longest ROH
regions do not need to necessarily coincide with the
disease susceptibility, we cannot exclude a possibility
that recessive variants, such as single nucleotide or
Figure 1 Population structure of Croatia Cohort. (A) FastME tree using IBS distance and (B) IBS distance multidimensional scaling (MDS) for
Croatia control + HGDP, colored by HGDP region IDs. (C) FastME tree using IBS distance and (D) IBS distance multidimensional scaling (MDS) for
Croatia Control + HGDP European Only, colored by HGDP subpopulation IDs.
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to disease susceptibility. To identify which regions con-
tribute to the significant difference between Croatia
case and control groups, we sorted the 7,740 endpoints
of all autosomal ROHs across Croatia case and control
groups, computed the significance of association
between ROH status and case/control status by Fish-
er’s test for each pair of adjacent ROH endpoints, and
examined the significance of each such ROH interval
where at least 5% (15) individuals have the ROH
(Table 5). The most significant ROHs are in two chro-
mosomal regions: chr2:82,040,863-82,677,336 (2p12)
and chr6:29,481,192-29,719,410 (6p21.1) (Figure 5 and
Figure 6). It is striking these two homozygosity regions
are near several genes previously associated with neu-
rological and psychiatric disorders. The chromosome 2
interval (636 Kb) is located downstream of CTNNA2
(alpha catenin) and LRRTM1 (leucine-rich repeat
transmembrane neuronal protein 1), and contains a
segment (between SNPs rs2685729 and rs2862972) sig-
nificantly enriched in ASD subjects (top p = 2.5 × 10
-
3). The LRRTM1 gene is associated with left-handed-
ness (patients with autism and many other psychiatric
disorders have a higher tendency to be left-handed
[39]) and may increase risk of schizophrenia [40,41].
The chromosome 6 interval (238 Kb) is a gene-rich
region located distal to the major histocompatibility
complex. This ROH is shared by 17 ASD subjects
(16.5%) and 19 controls (9.6%) spans 8 genes, including
a cluster of olfactory receptors (OR11A1, OR10C1,
OR2H1, OR2H2), the MOG locus, and the GABBR1
locus. The MOG gene (myelin oligodendrocyte glyco-
protein) is a transmembrane protein expressed on the
surface of myelin sheath, and may be involved in mul-
tiple sclerosis (OMIM#126200) [42,43]; recent studies
also found that MOG is differentially expressed in pre-
frontal cortex and temporal lobes in schizophrenic
patients [43,44]. The most significant interval (between
SNPs rs1233399 and rs29225; top p = 3.4 × 10
-3)
spans the 3’ end of the GABBR1 (Gamma-aminobuty-
ric acid (GABA) B receptor, 1) and the overlapping
UBD (Ubiquitin D) loci. GABBR1 is highly expressed
Figure 2 Pairwise IBS analysis. (A) Box-and-whisker plot of pairwise IBS distances for Croatia Control, subpopulations of HGDP European
Cohort, and the whole HGDP European Cohort. (B) Scatter plot of the first two coordinates of IBS distance multidimensional scaling (MDS) for
Croatia control, case, and NINDS control cohorts.
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date region for neuropsychiatric disorders [45,46]. A
recent study showed that the expression levels of
GABBR1 are significantly lower in several brain
regions in patients with autism compared with healthy
controls [47]. Finally, we examined the median IBS dis-
tances between the subjects with regions of homozyg-
osity on chromosomes 2 (13 Croatian cases and 10
Croatian controls) and chromosome 6 (17 Croatian
cases and 19 Croatian controls) with permutation tests,
but found that these subjects were not more closely
related than the population average. Thus, the
increased homozygosity in Croatia ASD cases cannot
be explained by inbreeding among close relatives in a
small number of selected families. However, the
observed homozygosity may be the result of shared
ancestral alleles from generations back in time.
Several studies have shown a role for copy number
variation in predisposing individuals to complex diseases
[48], including ASD [15,49-52]. To address this, we next
Figure 3 Analysis of median and mean cross-population pairwise IBS distances between Croatia Control and NINDS.( A )O b s e r v e d
median IBS distance and distribution of median IBS distances by random shuffling of population memberships; (B) observed mean IBS distance
and distribution of median IBS distances by random shuffling of population memberships.
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Cytoband Coordinate #SNP Mean Fst Median Fst Window/genomic
ratio of Mean Fst
Window/genomic
ratio of Median Fst
1q23.2-1q23.3 chr1:157.5-162.5 Mb 1031 0.00170 0.00078 1.47 1.51
1q31.3 chr1:192.5-197.5 Mb 663 0.00186 0.00064 1.61 1.23
2q21.2-2q22.1 chr2:132.5-137.5 Mb 854 0.00242 0.00105 2.10 2.02
2q21.3-2q22.1 chr2:135-140 Mb 653 0.00233 0.00089 2.02 1.71
3q26.1-3q26.2 chr3:165-170 Mb 592 0.00185 0.00101 1.60 1.95
4q31.21-4q31.22 chr4:142.5-147.5 Mb 571 0.00236 0.00124 2.05 2.38
4q31.22-4q31.23 chr4:145-150 Mb 644 0.00187 0.00078 1.62 1.51
5q21.3-5q22.1 chr5:105-110 Mb 866 0.00167 0.00078 1.45 1.51
5q22.1-5q22.3 chr5:110-115 Mb 930 0.00155 0.00083 1.34 1.59
5q31.1-5q31.3 chr5:135-140 Mb 599 0.00220 0.00084 1.91 1.62
6p22.2-6p21.33 chr6:25-30 Mb 951 0.00182 0.00081 1.58 1.56
6p22.1-6p21.32 chr6:27.5-32.5 Mb 1339 0.00280 0.00140 2.42 2.69
6p21.33-6p21.31 chr6:30-35 Mb 1524 0.00285 0.00133 2.47 2.57
6p21.32-6p21.2 chr6:32.5-37.5 Mb 1096 0.00204 0.00084 1.77 1.62
6p12.1-6p11.1 chr6:55-60 Mb 440 0.00162 0.00079 1.40 1.51
6q11.1-6q12 chr6:62.5-67.5 Mb 618 0.00168 0.00094 1.45 1.81
6q16.3-6q21 chr6:100-105 Mb 748 0.00157 0.00085 1.36 1.63
7q31.32-7q32.1 chr7:122.5-127.5 Mb 776 0.00143 0.00084 1.24 1.61
8q21.13-8q21.3 chr8:82.5-87.5 Mb 590 0.00143 0.00083 1.24 1.60
8q21.2-8q21.3 chr8:85-90 Mb 626 0.00201 0.00098 1.74 1.88
9q12-9q21.11 chr9:67.5-72.5 Mb 414 0.00170 0.00088 1.48 1.69
9q33.2-9q33.3 chr9:122.5-127.5 Mb 681 0.00156 0.00080 1.35 1.54
9q33.2-9q34.11 chr9:125-130 Mb 804 0.00157 0.00079 1.36 1.52
11p11.2-11p11.12 chr11:45-50 Mb 443 0.00177 0.00062 1.54 1.19
11q13.1-11q13.3 chr11:65-70 Mb 597 0.00170 0.00083 1.48 1.61
12p11.1-12q12 chr12:35-40 Mb 540 0.00148 0.00100 1.28 1.93
13q31.1-13q31.3 chr13:85-90 Mb 688 0.00156 0.00085 1.35 1.63
20q11.21-20q11.23 chr20:30-35 Mb 461 0.00163 0.00093 1.41 1.78
22q13.1-22q13.2 chr22:37.5-42.5 Mb 757 0.00159 0.00080 1.38 1.54
Table 3 Summary of the ROH comparison across Croatia Control, Croatia Case, and NINDS sample groups
#ROHs Total ROH length(KB) Average ROH length (KB)
Median
Croatia Ctrl 15 23486.3 1512.2
Croatia Case 16 26144 1519.3
NINDS 16 23909.3 1476.3
Wilcoxon Test P-value
Croatla Ctrl vs NINDS 0.0346 0.3928 0.0529
Croatla Case vs Ctrl 0.0413 0.0065 0.17
Croatla Case vs NINDS 0.6115 0.0248 0.0037
Kruskal-Wallis Test P-value
All three groups 0.0604 0.0279 0.0056
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ing data in Croatia cases and control subjects. We used
PennCNV [53], a high-resolution CNV detection
method, to call CNVs from the signal intensity data. We
identified 2,303 CNVs (using a 10-SNP threshold) in
304 subjects passing the quality control criteria (Table
6). The median size of CNVs is 71.4 Kb, while the mean
size of CNVs is 131.4 Kb. Due to the relatively small
sample size, we do not expect that we could detect asso-
ciation of specific CNVs with disease status; instead, we
focused on large and rare CNVs observed in cases but
n o tc o n t r o l s ,s i n c et h e ya r em o r el i k e l yt ob ed i s e a s e -
related. For example, a recent study identified large
(>500 Kb) CNVs to be especially pathogenic [54]; in
addition, a CNV study on schizophrenia demonstrates
that CNVs >500 Kb tend to be more prevalent in cases
versus controls [55-57], and that CNVs >2 Mb are
observed exclusively in cases [15,16].
Examining 299 unrelated individuals passing QC, we
identified a total of 32 CNVs >500 Kb, including 20
duplications and 12 deletions (Table 7 and Table 8).
These large chromosomal rearrangements, detected in
DNA samples isolated from blood (rather then cell
lines), were confirmed through signal intensity data for
the entire chromosome in the Illumina BeadStudio soft-
ware (data not shown). Among them, 5/103 cases
(4.85%) and 1/197 controls subject (0.49%) have CNVs
greater than 2 Mb. An exceptionally large CNV was
detected in an ASD female that harbored an 18 Mb
duplication on chromosome 7 (7q21.11-21.3), which
includes several known neurodevelopmental genes
(PCLO, SEMA3A, SEMA3C, SEMA3D and SEMA3E). A
duplication of this chromosomal region has been asso-
ciated with intellectual disability and multiple congenital
anomalies [58]. Another female has a 10 Mb deletion on
chromosome 11 (11q24.2-q25). The Jacobsen syndrome
(MIM147791) is a contiguous gene syndrome caused by
terminal deletions of the long arm of chromosome 11
and typically associated with growth and psychomotor
retardation and characteristic facial dimorphism [59].
Three of the ASD cases have multiple large rearrange-
ments; one adult male harbors two chromosomal rear-
rangements (separated by 117 Mb) on chromosome 1, a
335 Kb deletion on 1p35.3 and a 882 Kb duplication on
1q21.1 (Figure 7a). In a second individual (adult female)
we identified two distinct large CNVs: a 838 Kb deletion
in an intergenic region between GRM8 and POT1 on
7q31.33 (chr7:124,752,465-125,591,197) and a 691 Kb
deletion at 22q13.33 (chr22:48,833,840-49,524,956). This
deletion encompasses the SHANK3 gene and cytogenetic
rearrangements affecting this gene have been previously
associated with ASD [60,61]. It has been previously
reported that the 22q13 deletion syndrome, also known
as Phelan-McDermid syndrome (MIM606232), is char-
acterized by severe neonatal hypotonia and global devel-
opmental delay, normal to accelerated growth, absent to
severely delayed speech, and minor dysmorphic features
[62,63]. The third individual (male child) with multiple
large rearrangements harbors a 534 Kb intergenic dele-
tion at 2q21.1 (chr2: 129,716,352-130,250,751) and a
400 Kb duplication at 3q29 (chr3:195,987,870-
196,387,903). These large structural variants, especially
those found on multiple chromosomes illustrate the
need to combine high-density genotype analysis with
karyotype analysis to test for the presence of balanced
translocations and inversions.
In contrast to large rearrangements encompassing >10
Mbs that were observed in ASD cases, the largest rear-
rangement observed in control subjects is a 2.5 Mb
duplication at 15q24.1-q24.2 (chr15:70,783,089-
73,316,235), a known microdeletion/duplication region
[64]. Also, we found one control subject to have two
Figure 4 Scatter plots for ROH number and length versus Age
of Subject. (A) Total ROH length (in Kb) versus Age; (B) Number of
ROHs versus Age; (C) Average ROH size (in Kb) versus Age.
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Page 8 of 19duplications within the DiGeorge (MIM188400) and
Velocardiofacial (MIM192430) syndrome region on
chromosome 22 (22q11.21), a known pathogenic rear-
rangement hotspot where large (>1.5 Mb) deletions are
pathogenic [65]. These duplications (922 Kb in
chr22:17,690,812-18,613,429 and 563 Kb in
chr22:19,102,598-19,665,559) are separated by 489 Kb.
The observation that we see more large CNVs asso-
ciated with ASD subjects (>2 Mb: 5 cases, 1 control;
Fisher’s test; p = 0.019) suggests these large rearrange-
ments may be rare ASD susceptible variants; follow-up
investigations on larger cohorts will be necessary.
Conclusions
In this paper, we report analysis of a genome-wide high-
density genotype study for ASD in Croatia. The dataset,
although small, provides a distinctive opportunity to evalu-
ate structural variation associated with a complex disease
such as ASD in a genetically distinct population. In addi-
tion to the analysis of ASD, high-density genotype data
from a well-defined geographic area of Croatia permitted
also the study of the subjects’ g e n e t i cs u b s t r u c t u r ea n d
diversity. We asked whether the subjects included in this
study which were collected throughout Croatia, show a
lower level of genomic diversity in comparison to subjects
from other defined demographic areas. Addressing this
issue may suggest that a set of 100 Croatian ASD subjects
harbor a smaller set of susceptibility loci in comparison a
randomly selected set of ASD subjects from a larger area.
The Croatian samples represent a genetic continuum of
relatedness with a subset of individuals closer to those
from several regions in Europe, probably due to numerous
historic migrations. The impact of fine-scale population
history on the genetic substructure of individuals from
Croatia has recently been evaluated using a small set of
selected loci [21]. To our knowledge, this study is the first
to provide a genome-wide view of the genetic composition
of the Croatia population.
Although our study represents the first high-resolution
genomic analysis of subjects with ASD in Croatia, sev-
eral caveats need to be addressed. Apart from an
obviously limited sample size, the classification of ASD
subjects in this pilot project has been established using
the DSM-IV criteria. Due to phenotypic heterogeneity of
ASD and our finding of a wide-range of novel, and in
some cases, exceptionally large CNVs, there is a need
for accurate clinical diagnostic criteria for the diagnosis
of ASD and related neurodevelopmental syndromes.
Currently no other diagnostic tools were available in
Croatian; in order to compare our findings to those in
other large-scale genetic studies it will be necessary to
translate gold standard diagnostic tools such as ADOS
[66] and ADI-R [67] to Croatian and many other
languages.
We used PennCNV to call copy number variations,
though other CNV calling programs such as QuantiSNP
[68] and cnvPartition (a built-in software tool in the
Illumina BeadStudio software)are available An advantage
of using multiple CNV calling programs is to reduce
false positives, namely one can focus on CNVs returned
by multiple programs and expect them to be “more reli-
able”. Since our study focused on large CNVs (>500 Kb)
we were able to validate these variants by visual inspec-
tion of the raw intensities(data not shown).
We found that runs of homozygosity are more fre-
quent in Croatia ASD subjects than either Croatia or
NINDS control cohorts. Given the low frequency of
subjects with ROH, larger follow-up studies are neces-
sary to confirm the findings. Our findings suggest there
is a high chance that homozygosity mapping based on
family studies can discover rare recessive variants. Our
finding that several ASD subjects harbor exceptionally
large chromosomal rearrangements previously associated
with distinct clinical syndromes such as Velocardiofacial,
Jacobsen, Phelan-McDermid, or 3q29 microdeletion/
duplication syndromes (MIM609425; MIM611936) lends
support for cytogenetic or high-density genotype testing
for ASD subjects with complex clinical manifestation
[69]. Furthermore, recent findings that seemingly diverse
neurodevelopmental and neurological disorders are
often associated with the same chromosomal rearrange-
ment(s) provide support for in-depth phenotype analysis
and longitudinal clinical evaluation of entire families.
These family-based studies may also reveal whether
Table 4 Correlation between ROH and age
No. ROH Total ROH Size (Kb) Average ROH Size (Kb)
(Intercept) Coefficient 17.8 35677.3 2009.64
Coefficient -0.09 -328.5 -11.25
AGE P-value 0.409 0.322 0.303
Coefficient -0.71 -12177.4 -605.62
SEX(male) P-value 0.815 0.185 0.0463
Coefficient 0.087 564.4 23.26
AGE:SEX(male) P-value 0.467 0.119 0.0517
Wang et al. BMC Medical Genetics 2010, 11:134
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Page 9 of 19observed structural variants are de novo events or rather
inherited and present in additional family members. We
suggest that deeper population screens combined with
family-based genetic analyses will lead to improved
understanding of joint actions of associated loci and
molecular basis of neurodevelopmental disorders in
populations worldwide.
Methods
Subjects and DNA Preparation
The patient group consisted of 103 individuals (81 male,
22 female, mean age 21.5 ± 10.3, ranging from 4 to 45)
recruited from the Centers for Autism in Zagreb, Rijeka
and Split (Republic of Croatia) and diagnosed with aut-
ism spectrum disorders according to DSM-IV criteria.
Table 5 Top ROH regions in ROH association analysis
CHR START END SIZE (KB) #SNPs #ROH&Case #Case #ROH&Ctrl #Ctrl #ROH #Samples OR P
2 82040863 82067472 26610 3 11 103 8 198 19 301 2.83 0.0424
2 82067472 82143271 75800 11 11 103 7 198 18 301 3.25 0.0195
2 82143271 82146419 3149 3 12 103 7 198 19 301 3.58 0.0105
2 82146419 82235100 88682 18 12 103 8 198 20 301 3.12 0.0153
2 82235100 82276290 41191 6 12 103 9 198 21 301 2.76 0.0305
2 82276290 82330384 54095 4 12 103 8 198 20 301 3.12 0.0153
2 82330384 82342863 12480 2 13 103 8 198 21 301 3.42 0.0081
2 82342863 82367354 24492 7 12 103 8 198 20 301 3.12 0.0153
2 82367354 82677336 309983 20 12 103 7 198 19 301 3.58 0.0105
2 82677336 82706135 28800 3 12 103 5 198 17 301 5.06 0.0025
2 135475565 135478814 3250 2 4 103 21 198 25 301 0.34 0.0488
4 34049422 34100634 51213 8 30 103 37 198 67 301 1.78 0.0421
4 34100634 34156199 55566 7 30 103 36 198 66 301 1.85 0.0393
4 34156199 34179397 23199 5 29 103 35 198 64 301 1.82 0.0386
4 34378375 34397251 18877 3 26 103 30 198 56 301 1.89 0.0420
4 34531827 34538866 7040 2 17 103 16 198 33 301 2.24 0.0326
5 42508871 42588188 79318 9 11 103 8 198 19 301 2.83 0.0424
6 29481192 29574935 93744 17 16 103 15 198 31 301 2.24 0.0442
6 29574935 29591890 16956 7 16 103 14 198 30 301 2.41 0.0255
6 29591890 29602876 10987 3 15 103 13 198 28 301 2.42 0.0348
6 29602876 29607484 4609 2 15 103 11 198 26 301 2.89 0.0156
6 29607484 29623781 16298 3 16 103 11 198 27 301 3.11 0.0056
6 29623781 29638829 15049 5 16 103 10 198 26 301 3.44 0.0040
6 29638829 29639232 404 3 15 103 9 198 24 301 3.56 0.0034
6 29639232 29641274 2043 2 14 103 9 198 23 301 3.29 0.0101
6 29641274 29645954 4681 4 14 103 10 198 24 301 2.95 0.0131
6 29645954 29647461 1508 2 14 103 9 198 23 301 3.29 0.0101
6 29647461 29666169 18709 6 14 103 8 198 22 301 3.72 0.0042
6 29666169 29689020 22852 11 13 103 8 198 21 301 3.42 0.0081
6 29689020 29716673 27654 2 12 103 7 198 19 301 3.58 0.0105
6 29716673 29719410 2738 2 11 103 7 198 18 301 3.25 0.0195
6 29719410 29723801 4392 3 10 103 7 198 17 301 2.92 0.0356
6 61949597 62025463 75867 2 11 103 7 198 18 301 3.25 0.0195
6 62030461 62041958 11498 4 12 103 9 198 21 301 2.76 0.0305
7 69474084 69475255 1172 2 2 103 16 198 18 301 0.23 0.0392
8 51323785 51339189 15405 2 7 103 30 198 37 301 0.41 0.0416
12 33162179 33170263 8085 2 10 103 6 198 16 301 3.43 0.0266
12 33170263 33329348 159086 27 10 103 7 198 17 301 2.92 0.0356
12 33329348 33331881 2534 2 11 103 7 198 18 301 3.25 0.0195
12 33331881 33335472 3592 2 12 103 8 198 20 301 3.12 0.0153
12 33335472 33349548 14077 2 13 103 11 198 24 301 2.45 0.0426
12 49797511 49861882 64372 6 10 103 7 198 17 301 2.92 0.0356
Wang et al. BMC Medical Genetics 2010, 11:134
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Page 10 of 19The control group consisted of 203 healthy blood
donors (146 male, 57 female, mean age 32.5 ± 8.06, ran-
ging from 19 to 45) [30] with no history of mental ill-
nesses, behavioral disorders, or substance abuse. All
subjects were of Croatian (southern Slavic) origin. After
an informative talk, a written consent for inclusion in
the study was obtained from the control subjects and
from the patients’ parents. The study has been carried
out in accord with the Declaration of Helsinki, and was
approved by the Ethics Committee of the Medical
Faculty of the University of Zagreb.
Blood sampling was performed in the Centers for Aut-
ism (ASD cases) and in the Croatian Institute of Trans-
fusion Medicine (control subjects) between 9 and 11 a.
m. Either 2 or 5 ml of venous blood, depending on the
age of the participants, was collected into vacutainers
containing EDTA anticoagulant. DNA was isolated from
the whole blood using a DNA isolation kit for mamma-
lian blood (Boehringer Manheim, Germany).
Datasets and Preprocessing
The genomic DNA from blood was used to obtain geno-
types by the Illumina HumanHap550 version 3 high-
density array with 561,446 SNP markers. Coordinates of
SNPs as well as genomic annotations are based on
NCBI human genome build 36.3, (UCSC Genome Brow-
ser Release 18). The genotyping experiments were per-
formed at the Center for Applied Genomics, Children’s
Hospital of Philadelphia, as previously described [70].
The raw genotyping signal data were processed by the
Illumina BeadStudio software and converted to normal-
ized signal intensity values, represented as Log R Ratio
(LRR) and B Allele Frequency (BAF). Due to the pre-
sence of “g e n o m i cw a v ep a t t e r n s ” in some of the geno-
t y p e ds a m p l e s ,w ea p p l i e dad a t ap r e - p r o c e s s i n g
protocol [71] to increase the signal-to-noise ratio of the
LRR values for all samples.
We analyzed three genome-wide datasets: Croatia
Autism cohort (306 subjects), NINDS Control cohort
(542 subjects), and genotyping data from the Human
Genetic Diversity Panel (1043 subjects, genotyped at
Stanford University, downloaded from http://hagsc.org/
hgdp/files.html). The quality control (QC) procedure
(described in detail in Wang et al. [14] and Bucan et al.
[16]), done separately for the three datasets, is as fol-
lows: (1) we first discarded SNPs with 5% or more miss-
ing genotyping calls; (2) we then recomputed summary
statistics for individuals and markers; (3) we retained
Figure 5 UCSC Genome Browser genomic annotation around the region chr2:82,040,863-82,677,336. Genomic annotations of a region
where ROH status is associated with case/control status in the Croatia cohort.
Wang et al. BMC Medical Genetics 2010, 11:134
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Page 11 of 19Figure 6 UCSC Genome Browser genomic annotation around the region chr6:29,481,192-29,719,410. Genomic annotations of a region
where ROH status is associated with case/control status in the Croatia cohort.
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Page 12 of 19individuals/markers passing the following threshold:
individual - missing genotyping call percentage ≤5%;
marker - missing genotyping call percentage ≤5%, minor
allele frequency ≥5%. We then merged the Croatia
cohort with the NINDS control and HGDP datasets
separately into two combined datasets (Croatia samples
and HGDP, Croatia samples and NINDS), including all
individuals passing QC in their separate datasets, and
retaining only markers passing QC in both datasets.
Subpopulation membership for HGDP samples were
obtained from Supplemental material from Kidd et al.
[72].
To detect hidden related samples, we computed 
∧ ,
the estimated probability of IBD between every pair of
subjects from the Croatia control and case and NINDS
control samples using PLINK. We found 5 pairs of
Croatia control samples (but none among the case sam-
ples) and 4 pairs of NINDS control samples have 
∧ >
0.25 (siblings or closer). To be more specific, three
Croatia control pairs and one NINDS control pair have

∧ > 0.999 (duplicate genotyping or monozygotic twins),
and two Croatia Ctrl pairs and three NINDS control
pairs have 
∧ around 0.5 (first-degree relatives). To
reduce relatedness, in subsequent analysis, for each pair
we removed the one of the two samples with a larger
index number in the ROH analysis. Table 1 summarizes
the three genome-wide datasets analyzed in this paper.
IBS distance analysis
We computed the IBS (identity by state) distance
between any two subjects using PLINK, and constructed
three pairwise distance matrices: Croatia controls and
HGDP, Croatia controls and NINDS, Croatia cases and
controls. The IBS distance between two subjects is
defined as A+B/2, where A and B are the number of
SNPs that differ by one and two alleles between the two
subjects, respectively. We performed multidimensional
scaling using R [73] and plotted the first two coordi-
nates, and built trees using FastME, a distance-based
phylogeny reconstruction software [74].
FST Analysis
To quantitatively describe the genetic difference
between two population we next used the FST coefficient
(fixation coefficient). This measure combines informa-
tion across many loci in many individuals and a higher
FST v a l u ef o ral o c u si n d i c a t e sd i f f e r e n c eb e t w e e nt h e
genetic compositions in two populations, whereas FST =
0 implies no discernable difference between two popula-
tions at the locus.
We analyzed the FST values using the Croatia control
and NINDS control cohorts as follows. We first com-
puted the heterozygosity of each marker (defined as the
proportion of heterozygous individuals in the popula-
tion) using PLINK, then computed the fixation index
FST from the heterozygosity by R by the following steps.
(1) Compute the minor allele frequencies p1,p 2 and
p for the two subpopulations (with N1 and N2 subjects)
and the whole population (with N = N1 +N 2 subjects).
(2) Compute the expected proportion of heterozygotes
HT = p (1-p) assuming the two subpopulations are
genetically identical for the marker. (2) Compute the
expected proportion of heterozygotes HS =( N 1 p1 (1-p1)
+N 2 p2 (1-p2))/N. (3) Compute F H
H ST
S
T
=− 1 .
Runs of homozygosity
Runs of homozygosity (ROHs) are extended genomic
regions where the DNA sequences on the two chromo-
somes are identical, and may be due to identity by des-
cent or gene conversion; since polymorphic sites are all
homozygous, SNP arrays can be used to identify such
regions. Study of ROHs can provide information on the
population structure such as extent of inbreeding, and
can be used to find candidate genes in recessive disor-
ders. We computed the distribution of runs of homozyg-
osity for three groups (Croatia case, control, NINDS)
using PLINK with the following settings: an interval
passes as an ROH if it has 100 or more homozygous
SNPs (except at most one SNP), with density at least one
SNP every 50 Kb and at most 1 Kb gap between any two
neighboring SNPs. We ran Wilcoxon test between every
pair of the three groups, as well as Kruskal-Wallis test for
comparing three groups simultaneously.
Table 6 Summary of the CNV analysis
CNV size Croatian ASD (n = 103) Croatian controls (n = 197)
all Cn = 1 Cn = 3 all cn = 0 cn = 1 cn = 3 cn = 4
>500 Kb 14 (13.59%) 7 (6.80%) 7 (6.80%) 18 (9.14%) 1 (0.51%) 4 (2.03%) 12 (6.09%) 1 (0.51%)
>1 Mb 8 (7.77%) 4 (3.88%) 4 (3.88%) 8 (4.06%) 0 (0.00%) 3 (1.52%) 4 (2.03%) 1 (0.51%)
>2 Mb 5 (4.85%) 2 (1.94%) 3 (2.91%) 1 (0.51%) 0 (0.00%) 0 (0.00%) 1 (0.51%) 0 (0.00%)
Wang et al. BMC Medical Genetics 2010, 11:134
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Page 13 of 19Table 7 Large CNVs in the Croatia dataset: CNVs longer than 500 Kb in Croatia Cases
Chromosomal Region
(Cytogenetic
Coordinate)
Copy
No.
Length
(Kb)
No.
SNPs
Start SNP End SNP Genes Individual Sex Age
chr1:144943150-
145824905 (1q21.1)
3 882 207 rs6656361 rs11240147 ACP6, BCL9, CHD1L, FMO5, GJA5, PRKAB2 AC0037 m 31
chr2:129716352-
130250751 (2q21.1)
1 534 114 rs1251175 rs7578253 HS6ST1 (923711 bp upstream); RAB6C (202954 bp downstream) AC0068 m 9
chr2:199943597-
201740672 (2q33.1)
1 1,797 324 rs13028839 rs10200857 AOX1, BZW1, C2orf47, C2orf60, CFLAR, CLK1, FAM126B, FLJ38973, KCTD18, LOC26010, NDUFB3,
NIF3L1, ORC2L, PPIL3, SATB2, SGOL2
AC0086 m 11
chr4:189924391-
191164126 (4q35.2)
1 1,240 174 rs4863387 rs13120250 FRG1, TUBB4Q AC0025 m 22
chr7:124752465-
125591197 (7q31.33)
1 839 132 rs7810309 rs510319 POT1 (395192 bp upstream); GRM8 (274696 bp downstream) AC0058 f 35
chr7:78246495-97499079
(7q21.11-21.3)
3 18,681 3381 rs13308578 rs6960808 ABCB1, ABCB4, ADAM22, C7orf23, CACNA2D1, CD36, CROT, DBF4, DMTF1, GNAI1, GNAT3, GRM3,
HGF, KIAA1324L, MAGI2, MGC26647, PCLO, RUNDC3B, SEMA3A, SEMA3C, SEMA3D, SEMA3E,
SLC25A40, SRI, STEAP4, ZNF804BCLDN12, FLJ21062, GTPBP10, PFTK1, STEAP1, STEAP2,
ZNF804BACN9, AKAP9, ANKIB1, ASB4, ASNS, BET1
AC0015 m 20
chr10:41756307-
42461241 (10q11.1-
11.21)
3 705 49 rs10909011 rs158389 ZNF33B AC0061 m 17
chr10:54450683-
58765948 (10q21.1)
1 4,315 951 rs2249349 rs2928464 PCDH15, ZWINT AC0045 m 33
chr11:124367724-
134445626 (11q24.2-
q25)
1 10,078 2842 rs6590113 rs11224228 ACAD8, ACRV1, ADAMTS15, ADAMTS8, APLP2, B3GAT1, BARX2, C11orf38, C11orf45, CCDC15,
CDON, CHEK1, DCPS, DDX25, EI24, ETS1, FAM118B, FEZ1, FLI1, FOXRED1, GLB1L3, HNT, HYLS1,
IGSF9B, JAM3, KCNJ1, KCNJ5, KIRREL3, LOC219854, LOC89944, NCAPD3, NFRKB, OPCML, P53AIP1,
PATE, PKNOX2, PRDM10, PUS3, RICS
AC0052 f 26
chr12:37835456-
42584684 (12q12)
3 4,538 976 rs11170890 rs4488262 ABCD2, C12orf40, KIF21A, LRRK2, SLC2A13CNTN1ADAMTS20, GLT8D3, IRAK4, PDZRN4, PPHLN1,
PRICKLE1, PUS7L, TMEM117, TWF1, YAF2, ZCRB1
AC0093 m 17
chr16:15032942-
16197033 (16p13.11)
3 1,164 201 rs4985124 rs8056397 ABCC1, ABCC6, C16orf45, C16orf63, KIAA0430, MPV17L, MYH11, NDE1, NTAN1, PDXDC1, RRN3 AC0003 m 31
chr16:21482719-
29234430 (16p12.2-11.2)
3 7,175 1266 rs13339281 rs7500911 C16orf65, CDR2, CHP2, COG7, DCTN5, EARS2, EEF2K, ERN2, GGA2, HS3ST2, IGSF6, LOC23117,
METTL9, NDUFAB1, OTOA, PALB2, PLK1, POLR3E, PRKCB1, SCNN1B, SCNN1G, UBFD1, UQCRC2,
USP31, VWA3ACACNG3, PRKCB1, RBBP6AQP8, ARHGAP17, LCMT1, SLC5A11,
ZKSCAN2HS3ST4APOB48R, ATP2A1, ATXN2L, C16orf82, CCDC101
AC0088 m 15
chr17:28980655-
29960126 (17q12)
3 979 350 rs11657037 rs11657603 ACCN1, CCL1, CCL11, CCL13, CCL2, CCL7, CCL8, FLJ44815, TMEM132E AC0100 m 13
chr22:48833840-
49524956 (22q13.33)
1 691 126 rs137916 rs2285395 ACR, ADM2, ARSA, CHKB, CPT1B, ECGF1, FAM116B, HDAC10, KLHDC7B, LOC164714, LOC440836,
MAPK11, MAPK12, MAPK8IP2, MIOX, MLC1, MOV10L1, NCAPH2, PANX2, PLXNB2, SAPS2, SBF1,
SCO2, SELO, SHANK3, TMEM112B, TRABD, TUBGCP6
AC0058 f 35
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9Table 8 Large CNVs in the Croatia dataset: CNVs longer than 500 Kb in Croatia Controls
Chromosomal Region
(Cytogenetic
Coordinate)
Copy
No.
Length
(Kb)
No.
SNPs
Start SNP End SNP Genes Individual Sex Age
chr2:836164-1827317
(2p25.3)
3 991 202 rs4533500 rs11127313 LOC391343, MYT1L, PXDN, SNTG2, TPO Aut_26 m 28
chr3:186745-1313259
(3p26.3)
3 1,127 339 rs6442427 rs1353825 CHL1, CNTN6 Aut_46 f 36
chr3:57010-1122201
(3p26.3)
3 1,065 267 rs1516321 rs6797539 CHL1, CNTN6 Aut_99 m 14
chr4:188763338-
190322725 (4q35.2)
1 1,559 333 rs13147499 rs13106777 FLJ25801, TRIML1, ZFP42 Aut_37 m 27
chr4:190385789-
190982886 (4q35.2)
3 597 69 rs10446846 rs6844114 TRIML1 (1080146 upstream); FRG1 (116082 downstream) Aut_141 m 20
chr5:104486852-
105008254 (5q21.2-21.3)
3 521 58 rs294152 rs6872786 NUDT12 (1560463 upstream); EFNA5 (1735996 downstream) Aut_36 f 29
chr7:49000866-49879997
(7p12.3-12.2)
3 879 165 rs1004168 rs6963083 VWC2 Aut_203 f 20
chr7:79347222-81014740
(7q21.11)
1 1,668 336 rs6949571 rs2909580 CD36, GNAI1, GNAT3, SEMA3C Aut_65 m 8
chr8:4005541-4886423
(8p23.2)
1 881 781 rs7006672 rs7815159 CSMD1 Aut_38 f 25
chr8:85925158-87860757
(8q21.2-21.3)
1 1,936 257 rs4740033 rs11781187 ATP6V0D2, C8orf59, CA1, CA13, CA2, CA3, CNGB3, CPNE3, E2F5, FAM82B, LRRCC1, PSKH2, RALYL,
REXO1L1, SLC7A13, WWP1
Aut_114 f 29
chr9:22934927-23536461
(9p21.3)
3 602 136 rs1463014 rs7028484 DMRTA1 (492455 upstream); ELAVL2 (143644 downstream) Aut_54 m 27
chr12:33415349-
34701470 (12p11.1)
4 1,286 104 rs1905414 rs9706509 ALG10, SYT10 Aut_39 m 23
chr15:70783089-
73316235 (15q24.1-24.2)
3 2,533 382 rs11072382 rs1565496 ADPGK, ARID3B, BBS4, C15orf17, C15orf39, CCDC33, CD276, CLK3, COX5A, CPLX3, CSK, CYP11A1,
CYP1A1, CYP1A2, EDC3, GOLGA6, HCN4, ISLR, ISLR2, LMAN1L, LOC283677, LOC388135, LOXL1,
MPI, NEO1, NPTN, PML, PPCDC, RPP25, SCAMP2, SCAMP5, SEMA7A, STOML1, STRA6, TBC1D21,
UBL7, ULK3
Aut_10 m 48
chr16:76525505-
77164850 (16q23.1)
3 639 235 rs387138 rs2346008 CLEC3A, KIAA1576, WWOX Aut_148 m 38
chr22:17690812-
18613429 (22q11.21)
3 923 248 rs982520 rs854971 ARVCF, C22orf25, C22orf29, CDC45L, CLDN5, COMT, DGCR8, GNB1L, GP1BB, HIRA, HTF9C,
LOC128977, MRPL40, RANBP1, RTN4R, SEPT5, TBX1, TXNRD2, UFD1L, ZDHHC8
Aut_94 m 6
chr22:19102598-
19665559 (22q11.21)
3 563 97 rs738089 rs7292968 AIFM3, CRKL, KLHL22, MED15, PI4KA, SCARF2, SERPIND1, SNAP29 Aut_94 m 6
chrX:6468166-8112188
(Xp22.31)
3 1,644 190 rs6654819 rs2278935 HDHD1A, PNPLA4, STS, VCX, VCX2 Aut_157 f 41
chrX:93063380-93732495
(Xq21.32-21.33)
0 669 88 rs6615574 rs5950049 FAM133A (209463 upstream); DIAPH2 (2093870 downstream) Aut_155 m 38
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9Figure 7 CNV status of AGRE, NINDS control, and Croatia ASD/control cohorts. (A) CNVs around four candidate genes (ACP6, CHD1L, FMO5,
and PRKAB2) in 882 kb duplication on 1q21.1 (chr1:144,943,150-145,824,905). (B) Duplication of size 979 kb around the neuronal amiloride-
sensitive cation channel gene (ACCN1) on Chr 17q11.2-q12 (chr17:28,000,000-30,100,000).
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Page 16 of 19To identify genomic regions where the ROH sta-
tus correlates with the case/control status, we ran
Fisher’st e s ta sf o l l o w s :w ef i r s ts o r t e dt h e7 , 7 6 6
endpoints of all autosomal ROHs across Croatia
case and control groups; for each pair of adjacent
endpoints, we computed the significance of associa-
tion between ROH status and case/control status
by Fisher’st e s t .
Correlation between ROH and age
M o t i v a t e db yt h es t u d yd e m o n s t r a t i n gt h ep o s i t i v ec o r -
relation between runs of homozygosity and age in a
North American cohort of European descent due to
urbanization [35], we examined the correlation between
age and ROH frequency and size. Only the 103 ASD
subjects have age information. We used age and sex as
covariates in a full linear regression model (in R/S-Plus
specification):
Y AGE SEX ~*
Here the dependent variable can be either the total
ROH length, average ROH length, or number of ROH
regions in a subject.
CNVs analysis
A previously described high-resolution CNV detection
algorithm, the PennCNV algorithm [53], was used to
infer CNVs from the signal intensity data following pro-
tocols described in Wang et al. [53] The PennCNV algo-
rithm uses a Hidden Markov model to identify any
genomic regions with duplications or deletions by com-
bining signal intensity and SNP allelic ratio distribu-
tions. The Illumina BeadStudio software provided
visualization tools that were used to display signal inten-
sity data for the entire chromosome.
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